Chinese expert consensus on precision diagnosis and treatment of refractory tumors

Area of Science:

• Oncology
• Genomics
• Precision Medicine

Background:

• Refractory tumors, including rare and treatment-resistant malignancies, present significant clinical challenges.
• Genomic and tumoral heterogeneity contribute to treatment resistance.
• A lack of consensus exists regarding the optimal management of these complex cases.

Purpose of the Study:

• To develop evidence-based guidelines for the diagnosis and treatment of refractory tumors.
• To establish a standardized framework for precision oncology in China.
• To address the heterogeneity and complexity of rare and treatment-resistant cancers.

Main Methods:

• Formation of the China Consortium for Precision Diagnosis and Therapeutics in Refractory Tumors (CCPT).
• Development of evidence-based guidelines integrating established frameworks and clinical expertise.
• Introduction of a Chinese-specific classification system for refractory tumors.

Main Results:

• CCPT has developed comprehensive guidelines for refractory tumors.
• Recommendations cover multi-omics testing, personalized therapy, and combination strategies.
• A Chinese-specific classification system and guidelines for dose optimization and data-sharing were introduced.

Conclusions:

• The CCPT guidelines aim to standardize practice in precision oncology for refractory tumors.
• These guidelines will advance integrated precision care for rare and treatment-resistant malignancies.
• The initiative promotes a multidisciplinary approach to complex cancer treatment.